
|Articles|July 1, 2003
Psoriasis Summit
San Francisco - While the 2002 Psoriasis Therapies Educational Summit Meeting successfully fostered various educational programs about new and emerging modalities for psoriasis treatment, many questions still linger, Jeffrey P. Callen, M.D., told attendees of the annual meeting of the American Academy of Dermatology. Specifically, questions regarding the use of biologic agents remain unable to be answered, Dr. Callen said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














